Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-driven therapies in persistent or recurrent rare epithelial ovarian tumors
2020-004936-72Phase 2Active
- Sponsor
- Roche
- Start
- Apr 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipatasertib, atezolizumab, cobimetinib, trastuzumab emtansine, bevacizumab and 1 more in epithelial ovarian cancer (EOC) and ovarian cancer (4 arms), sponsored by Roche. Primary endpoint: Confirmed objective response rate. Started Apr 2021; status: active.
02
Drugs
ipatasertibatezolizumabcobimetinibtrastuzumab emtansinebevacizumab
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on 2020-004936-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004936-72.